INNATE PHARMA SA (IPH.PA) Stock Earnings & Estimates
Europe - Euronext Paris - EPA:IPH - FR0010331421 - Common Stock
1.506 EUR
+0 (+0.13%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 49.58M 309.35% | 51.901M 4.68% | 12.622M -75.68% | 24.606M 94.95% | 35.409M 43.90% | 35.811M 1.14% | 64.861M 81.12% | 172.6M 166.11% | 193.17M 11.92% | 248.85M 28.82% | 306.7M 23.25% | 440.9M 43.76% | |
| EBITDA YoY % growth | 28.98M 167.04% | -7.578M -126.15% | -49.581M -554.28% | -10.912M 77.99% | 71.305M 753.45% | 98.472M 38.10% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -16.425M 65.66% | -12.669M 22.87% | -51.575M -307.10% | -26.989M 47.67% | 22.38M 182.92% | -28.829M -228.82% | -65.419M -126.92% | 42.044M 164.27% | 65.447M 55.66% | 105.83M 61.70% | 134.82M 27.39% | N/A | |
| Operating Margin | -33.13% | -24.41% | -408.61% | -109.68% | 63.20% | -80.50% | -100.86% | 24.36% | 33.88% | 42.53% | 43.96% | N/A | |
| EPS YoY % growth | N/A 72.93% | N/A -169.82% | N/A 23.22% | -0.54 -32.84% | -0.50 8.46% | -0.45 9.31% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in EUR
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 | -0.12 | -0.12 -9.09% | -0.07 72.00% | -0.13 -8.33% | -0.10 16.67% | -0.13 -8.33% | -0.13 -85.71% | -0.09 30.77% | -0.13 -30.00% |
| Revenue Q2Q % growth | 1.98M | 2.172M -49.83% | 2.222M -54.35% | 7.817M 367.80% | 2.293M 15.81% | 2.404M 10.68% | 2.353M 5.90% | 2.788M -64.33% | 9.878M 330.79% | 6.989M 190.72% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.857M | -12.665M 49.86% | -13.019M -34.83% | -8.211M 67.71% | -13.645M -6.13% | -16.17M -27.67% | -19.766M -51.82% | -19.443M -136.78% | -14.685M -7.62% | -19.917M -23.17% |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -0.59 -629.56% | % |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 1.671M -79.85% | 4.909M | -3.238M | -65.96% |
| Q4 2024 Q2Q % growth | 4.329M -73.85% | % | ||
| Q2 2024 Q2Q % growth | 8.293M -76.54% | % | ||
| Q4 2023 Q2Q % growth | 16.557M 99.27% | % | ||
| Q2 2023 Q2Q % growth | 35.344M -14.36% | % | ||
| Q4 2022 Q2Q % growth | 8.309M 118.20% | % | ||
| Q2 2022 Q2Q % growth | 41.271M 397.00% | % | ||
| Q4 2021 Q2Q % growth | 3.808M -85.53% | % | ||
| Q2 2021 Q2Q % growth | 8.304M -72.17% | % | ||
| Q4 2020 Q2Q % growth | 26.31M | 27.379M | -1.069M | -3.90% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -230.42% |
| Revenue | 0% | 0% | 0% | -18.95% |